Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.

IRVINE, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting data at the 2023 American Association of Cancer Research (AACR) Annual Meeting ...

Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor ...

Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors ...

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...

Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...